An observational study in Healthy, IBS - Irritable Bowel Syndrome and Inflammatory Bowel Diseases, sponsored by Stanford University. Not yet recruiting. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by Stanford University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
GI disorders are influenced by the gut microbiome. To date, sampling of the small intestine in GI disorders has been limited. The investigators plan to sample the small intestinal contents during endoscopy for research purposes.
Current guidelines (AGA Clinical Practice Update, 2020) report the definition of SIBO as a clinical entity lacks precision and consistency; it is a term generally applied to a clinical disorder where symptoms, clinical signs, and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine. To date, there is unlimited knowledge regarding the diagnostic criterion which has been limited by nonspecific and nonsensitive testing such as breath tests. Breath tests have a limited use in patients with IBS-D who inherently have increased gut transit time rendering the testing invalid for accurately measuring small intestinal bacteria. Additionally, the relationship between SIBO and symptoms in patients without obvious risk factors (such as anatomical changes due to surgery) is unknown. The investigators study aims to investigate the microbial landscape of the small intestine in healthy patients and those with GI disease (suspected or diagnosed) undergoing an upper endoscopy by collecting an aspirate of patient small intestinal fluid and studying it.
1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.
This study's planned enrollment of 150 is close to the median of 161 across 192 observational studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients seen at Stanford University Digestive Health Center who are scheduled for an upper endoscopy as part of their Standard Of Care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children (under age 18years) Pregnant Women and Fetuses Neonates (0 - 28 days) Impaired Decision Making Capacity
We will collect luminal fluid via endoscopic sampling
Ability to isolate live bacteria from 95% of samples
We aim to isolate live bacteria from 95% of samples
Time frame: 1-4 years
Ability to measure quantitative Colony Forming Units (CFUs) in 90% of samples
We aim to measure quantitative Colony Forming Units (CFUs) in 90% of samples
Time frame: 1-4 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2024; primary completion for Jan 2026, 24 months later.
Of 52 non-industry observational studies under Irritable Bowel Syndrome, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 193. This study's planned 24 months is below that.
Counting every sponsor, half of 66 studies reached it within 42 months; a quarter within 21 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.